Positive Update on IMP761 Phase 1
Filed with ASX · · 2 pages · English
• Given encouraging efficacy and safety, the trial will continue as planned and further updates are anticipated in 1H CY2026 including presentation of data at a major medical conference SYDNEY, AUSTRALIA – December 22, 2025 – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces a positive
Earlier from Immutep
- Immutep Announces Strong Operational Progress in Global TACTI-004 (KEYNOTE-F91) Phase III and Enrolment Continues at Robust Pace
- TACTI-004 phase III trial enrolment continues at robust pace
- Immutep and Dr. Reddy’s enters into Strategic Collaboration for Commercialisation of an Innovative Oncology Drug, Eftilagimod Alfa
- Immutep enters into Strategic Collaboration with Dr. Reddy's
- Immutep to Present New Data from AIPAC-003 Phase II at the 2025 San Antonio Breast Cancer Symposium
Later from Immutep
- Immutep Announces Positive Update on IMP761, a First-in-Class LAG-3 Agonist Antibody for Autoimmune Diseases, from Phase I Study
- Immutep Quarterly Activities Report and Appendix 4C
- Immutep Quarterly Activities Report Q2 FY26
- Immutep Achieves 50% Enrolment in Global TACTI-004-1L NSCLC
- Immutep Achieves 50% Enrolment in Global TACTI-004 (KEYNOTE-F91) Phase III Trial in 1L NSCLC
Follow Immutep into a list and get an email when it puts out news.
Follow Immutep